Macari, D M <br/><br/>
Priming of eosinophil recruitment in vivo by LPS pretreatment.  [electronic resource] 

 -  Journal of immunology (Baltimore, Md. : 1950)  Aug 1996 
 - 1684-92 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0022-1767 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal--pharmacology<br/>Antigens, CD--genetics<br/>Azepines--pharmacology<br/>CD18 Antigens--immunology<br/>Chemotactic Factors, Eosinophil--pharmacology<br/>Chemotaxis, Leukocyte--drug effects<br/>Complement C5a, des-Arginine--pharmacology<br/>Cycloheximide--pharmacology<br/>Drug Synergism<br/>Edema--chemically induced<br/>Eosinophilia--chemically induced<br/>Eosinophils--drug effects<br/>Female<br/>Guinea Pigs<br/>Immunoglobulin G--pharmacology<br/>Interleukin 1 Receptor Antagonist Protein<br/>Leukocyte Count--drug effects<br/>Leukotriene B4--pharmacology<br/>Lipopolysaccharides--pharmacology<br/>Lipoxygenase Inhibitors--pharmacology<br/>Neutrophils--drug effects<br/>Passive Cutaneous Anaphylaxis<br/>Platelet Activating Factor--antagonists & inhibitors<br/>Protein Synthesis Inhibitors--pharmacology<br/>Pyrans--pharmacology<br/>Quinolones--pharmacology<br/>Receptors, Tumor Necrosis Factor--genetics<br/>Receptors, Tumor Necrosis Factor, Type I<br/>Recombinant Fusion Proteins--pharmacology<br/>Sialoglycoproteins--pharmacology<br/>Skin--drug effects<br/>Triazoles--pharmacology<br/>Zymosan--pharmacology